Standout Papers

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cel... 2005 2026 2012 2019 1.5k
  1. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study (2009)
    Daniel Y.C. Heng, Wanling Xie et al. Journal of Clinical Oncology
  2. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma (2005)
    Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology
  3. Renal cell carcinoma (2009)
    Brian I. Rini, Steven C. Campbell et al. The Lancet
  4. Sunitinib in Patients With Metastatic Renal Cell Carcinoma (2006)
    Robert J. Motzer, Brian I. Rini et al. JAMA
  5. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014)
    Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology
  6. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study (2013)
    Daniel Y.C. Heng, Wanling Xie et al. The Lancet Oncology
  7. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 (2008)
    Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology
  8. Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009)
    Jennifer S. Ko, Arnold H. Zea et al. Clinical Cancer Research
  9. Treatment of renal cell carcinoma: Current status and future directions (2017)
    Pedro C. Barata, Brian I. Rini CA A Cancer Journal for Clinicians
  10. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial (2013)
    Robert J. Motzer, Bernard Escudier et al. The Lancet Oncology
  11. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020)
    Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology
  12. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011)
    Brian I. Rini, Dongrui R. Lu et al. JNCI Journal of the National Cancer Institute
  13. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study (2017)
    Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology
  14. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020)
    Laurence Albigès, Nizar M. Tannir et al. ESMO Open
  15. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer (2007)
    Eric J. Small, N. Simon Tchekmedyian et al. Clinical Cancer Research
  16. The immunology of renal cell carcinoma (2020)
    C. Marcela Díaz‐Montero, Brian I. Rini et al. Nature Reviews Nephrology

Immediate Impact

43 by Nobel laureates 9 from Science/Nature 127 standout
Sub-graph 1 of 18

Citing Papers

Renal Cell Carcinoma
2024 Standout
Renal cell carcinoma
2024 Standout
27 intermediate papers

Works of Brian I. Rini being referenced

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
2023
and 53 more

Author Peers

Author Last Decade Papers Cites
Brian I. Rini 25164 15310 19308 761 37.4k
Bernard Escudier 26197 14176 22473 712 40.8k
Ronald M. Bukowski 19691 13215 17507 454 33.5k
Robert A. Figlin 25082 11928 21802 467 37.4k
Stéphane Oudard 26909 13527 16290 611 37.9k
Robert J. Motzer 38543 19079 30079 921 57.3k
Yi‐Long Wu 34177 28203 12328 1.0k 44.6k
Jean‐Charles Soria 12561 19265 12792 675 34.0k
Nicholas J. Vogelzang 22117 16878 8203 693 40.8k
Tony Mok 38626 34880 15477 671 55.0k
Martin Gore 8895 14140 12791 377 29.0k

All Works

Loading papers...

Rankless by CCL
2026